Sugi Predict

Sugi Predict / Compounds / SCHEMBL4876756

SCHEMBL4876756

SCHEMBL4876756

O=[N+]([O-])c1ccc(-n2ccnc2)nc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.53
▸ ALDH1A1 P00352 3/20 0.51
▸ LMNA P02545 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ CYP1A2 P05177 2/20 0.49
▸ CYP2C9 P11712 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ KMT2A Q03164 6/20 0.47
▸ MEN1 O00255 4/20 0.47
▸ ATM Q13315 1/20 0.47
▸ CYP19A1 P11511 4/20 0.47
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ NPBWR1 P48145 1/20 0.41
▸ MCHR1 Q99705 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30753605 1.00 MAPT (0.53) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL27929641 0.80 MAPT (0.58) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL1067002 0.77 CYP19A1 (0.55) MAPTLMNAKMT2AMEN1CYP19A1
SCHEMBL16687191 0.74 MAPT (0.51) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL11900313 0.74 MAPT (0.51) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL19036206 0.73 GRIK1 (0.49) MAPTKMT2ACYP19A1
SCHEMBL4185751 0.72 LMNA (0.54) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL30522724 0.72 LMNA (0.54) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL18118206 0.72 CHRNA7 (0.50) ALDH1A1LMNACYP1A2CYP2C9KMT2A
SCHEMBL9113748 0.72 MAPT (0.53) MAPTALDH1A1LMNAALOX12NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606544-B2 JAK1 selective kinase inhibitor DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2026-04-21 — — US disclosed
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof GISMO THERAPEUTICS, INC. 2024-12-05 — — US disclosed
CN-117999075-A Compounds and pharmaceutical compositions comprising inhibitors of amyloid peptide interaction with glycosaminoglycans, methods of treatment, and uses thereof 吉斯莫治疗股份有限公司 2024-05-07 — — CN disclosed
CN-113710664-B JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2024-01-26 — — CN disclosed
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-07-14 — — US disclosed
EP-3956322-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-02-23 — — EP disclosed
CN-113710664-A JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2021-11-26 — — CN disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 — — WO disclosed
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 — — EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 — — US disclosed
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER INC 2008-04-17 — — US disclosed
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER INC 2008-04-17 — — US disclosed
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PFIZER INC 2008-04-17 — — US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 — — US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 — — US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 — — US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 — — US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 — — US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 — — US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR JAK1, JAK2, JAK3 MAPT 3488/4885ALDH1A1 1434/4885LMNA 4788/4885
US-20240398783-A1 Compounds and Pharmaceutical Compositions Comprising Inhibitors of Amyloid Peptide Interactions with Glycosaminoglycans, Methods of Treatment and Use Thereof PRNP, GBA1, GBA3 MAPT 73/4885ALDH1A1 3486/4885LMNA 2032/4885
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 MAPT 3337/4885ALDH1A1 1300/4885LMNA 3033/4885
US-20080090834-A1 SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS PDE5A, PDE3B, PDE12 MAPT 964/4885ALDH1A1 204/4885LMNA 3434/4885
US-12606544-B2 JAK1 selective kinase inhibitor JAK1, JAK2, JAK3 MAPT 4828/4885ALDH1A1 1845/4885LMNA 4435/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 MAPT 3337/4885ALDH1A1 1300/4885LMNA 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.